Zaltrap
Generic: Aflibercept
Daily Dose:
Course Duration:
Cheaper & Alternative Brands (100 mg/4 ml)
Same active generic (Aflibercept), same form (IV Infusion), exact same strength (100 mg/4 ml)No other brands currently registered with this exact active generic and dosage form.
Clinical Prescribing Information
Medical monograph and safety information for healthcare professionals & patients.Indications & Clinical Uses
Zaltrap, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen.
Side Effects & Adverse Reactions
Most common adverse reactions (all grades, ≥20% incidence and at least 2% greater incidence for the Zaltrap/FOLFIRI regimen) were leukopenia, diarrhea, neutropenia, proteinuria, AST increased, stomatitis, fatigue, thrombocytopenia, ALT increased, hypertension, weight decreased, decreased appetite, epistaxis, abdominal pain, dysphonia, serum creatinine increased, and headache
Warnings & Precautions
Adverse reactions, sometimes severe and life-threatening or fatal, have been seen in clinical trials with Zaltrap, including:
Fistula Formation: Discontinue Zaltrap if fistula occurs.
Hypertension: Monitor blood pressure and treat hypertension. Temporarily suspend Zaltrap if hypertension is not controlled. Discontinue Zaltrap if hypertensive crisis develops.
Arterial Thromboembolic Events (ATE) (e.g., transient ischemic attacks, cerebrovascular accident, angina pectoris): Discontinue Zaltrap if ATE develops.
Proteinuria: Monitor urine protein. Suspend Zaltrap when proteinuria ≥ 2 grams per 24 hours. Discontinue Zaltrap if nephrotic syndrome or thrombotic microangiopathy (TMA) develops.
Neutropenia and Neutropenic Complications: Delay administration of Zaltrap/FOLFIRI until neutrophil count is ≥ 1.5 × 109/L.
Diarrhea and Dehydration: Incidence of severe diarrhea and dehydration is increased. Monitor elderly patients more closely.
Reversible Posterior Leukoencephalopathy Syndrome (RPLS): Discontinue Zaltrap.
Pharmacology & Mechanism of Action
Ablibercept is a recombinant fusion protein that acts as a decoy receptor for the ligands, vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PIGF). It prevents these ligands to binding to endothelial receptors, VEGFR-1 and VEGFR-2, to suppress neovascularization and decrease vascular permeability. This ultimately will slow vision loss or the progression of metastatic colorectal cancer.